| Literature DB >> 24445259 |
Elham S Darwish1, Azza M Abdel Fattah2, Fawzy A Attaby3, Oqba N Al-Shayea4.
Abstract
This study aimed for the synthesis of new heterocyclic compounds incorporating sulfamoyl moiety suitable for use as antimicroEntities:
Mesh:
Substances:
Year: 2014 PMID: 24445259 PMCID: PMC3907866 DOI: 10.3390/ijms15011237
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1.Synthesis of cyanoacetamide 3.
Scheme 2.Synthesis of arylidene 5a–c and pyridones 7a–c and 10.
Scheme 3.Synthesis of 2-imino-2H-chromene 11 and 2-oxo-2H-chromene 12.
Scheme 4.Synthesis of hydrazones 13a–e and aminopyrazole 14a,b.
Scheme 5.Synthesis of aminothiazole 15 and diaminothiophene 16.
Scheme 6.Synthesis of thiazoles 18, 19 and acrylamide 20.
Scheme 7.Synthesis of 1,3-dithian-2-ylidene 22.
Antibacterial and antifungal activities of the synthesized compounds (5a, 5c, 7b, 7c, 10, 11, 13b, 14a, 15, 16, 18, 19 and 22).
| Comp. | Inhibition zone diameter (cm) | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Gram (+) | Gram (−) | Fungi | ||||||
|
| ||||||||
| Standard values | ||||||||
|
| ||||||||
| 23.8 ± 0.2 | 32.4 ± 0.3 | 17.3 ± 0.1 | 19.9 ± 0.3 | 23.7 ± 0.2 | 19.7 ± 0.2 | 28.7 ± 0.2 | 25.4 ± 0.1 | |
| 18.9 ± 0.44 | 21.7 ± 0.25 | 11.6 ± 0.19 | 15.4 ± 0.39 | 20.2 ± 0.55 | 16.3 ± 0.25 | 22.4 ± 0.58 | 19.6 ± 0.33 | |
| 16.3 ± 0.55 | 18.3 ± 0.25 | NA | NA | 17.3 ± 0.44 | 12.6 ± 0.25 | 19.0 ± 0.58 | 16.9 ± 0.25 | |
| 16.9 ± 0.58 | 18.2 ± 0.44 | NA | 11.9 ± 0.63 | 15.7 ± 0.33 | 13.8 ± 0.25 | 18.3 ± 0.34 | NA | |
| 18.3 ± 0.25 | 22.6 ± 0.44 | 13.1 ± 0.32 | 20.3 ± 0.09 | 20.6 ± 0.58 | 16.7 ± 0.33 | 22.4 ± 0.36 | 17.6 ± 0.58 | |
| 16.7 ± 0.36 | 19.2 ± 0.27 | NA | 13.6 ± 0.36 | 16.8 ± 0.39 | 13.4 ± 0.58 | 19.6 ± 0.19 | 15.9 ± 0.44 | |
| NA | NA | NA | NA | 15.7 ± 0.36 | 11.2 ± 0.33 | 17.3 ± 0.44 | 13.3 ± 0.36 | |
| 12.3 ± 0.58 | 12.7 ± 0.37 | NA | 8.5 ± 0.37 | 17.6 ± 0.58 | 15.4 ± 0.25 | 12.6 ± 0.38 | NA | |
| 17.5 ± 0.44 | 19.8 ± 0.63 | NA | 18.9 ± 0.25 | 15.3 ± 0.55 | 13.4 ± 0.35 | 11.5 ± 0.58 | NA | |
| 15.0 ± 0.43 | 17.4 ± 0.53 | 12.3 ± 0.25 | 17.8 ± 0.03 | 11.3 ± 0.34 | 12.1 ± 0.25 | 15.3 ± 0.38 | NA | |
| NA | NA | NA | NA | NA | NA | NA | NA | |
| 16.9 ± 0.58 | 18.2 ± 0.44 | NA | 11.9 ± 0.63 | 16.2 ± 0.36 | 15.0 ± 0.44 | 17.6 ± 0.58 | NA | |
| 12.9 ± 0.63 | 13.2 ± 0.58 | NA | 10.8 ± 0.44 | 18.7 ± 0.36 | 16.9 ± 0.27 | 13.4 ± 0.65 | NA | |
| 12.3 ± 0.58 | 12.7 ± 0.37 | NA | 10.8 ± 0.44 | 17.6 ± 0.58 | 15.4 ± 0.25 | 12.6 ± 0.38 | NA | |
Data are expressed in the form of mean ± SD. Mean zone of inhibition in mm ± standard deviation beyond well diameter; (6 mm) produced on a range of environmental and clinically pathogenic microorganism using (5 mg/mL) concentration of tested sample (100 μL was tested).